ABIOMED, Inc.  

(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for ABMD
35.52
-0.26 (-0.73%)
Nov 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.41 - 36.09
52 week 20.29 - 36.37
Open 35.77
Vol / Avg. 140,656.00/434,791.00
Mkt cap 1.46B
P/E 148.76
Div/yield     -
EPS 0.24
Shares 40.89M
Beta 1.69
Inst. own 117%
Jan 28, 2015
Q3 2015 Abiomed Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 3, 2014
Abiomed Inc at Piper Jaffray Healthcare Conference - 12:00PM EST - Add to calendar
Nov 20, 2014
Abiomed Inc at Jefferies Global Healthcare Conference - London
Nov 11, 2014
Abiomed Inc at Stephens Fall Investment Conference
Oct 30, 2014
Q2 2015 Abiomed Inc Earnings Release
Oct 30, 2014
Q2 2015 Abiomed Inc Earnings Call
Sep 10, 2014
Abiomed Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 7.39% 4.00%
Operating margin 8.04% 4.55%
EBITD margin - 5.92%
Return on average assets 7.30% 3.92%
Return on average equity 8.90% 4.81%
Employees 511 -
CDP Score - -

Address

22 CHERRY HILL DR
DANVERS, MA 01923
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ABIOMED, Inc., is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. In April 2014, the Company acquired exclusive license from collaboration partner Opsens Inc. In July 2014, Abiomed Inc acquired ECP Entwicklungsgesellschaft mbH (ECP), medical device company based in Berlin, Germany, and AIS GmbH Aachen Innovative Solutions through ECP.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Bowen Chief Financial Officer, Vice President, Treasurer
Age: 64
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President - Global Product Operations
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 41
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 50
Bio & Compensation  - Reuters
Ingrid Goldberg Director - Investor Relations
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Eric A. Rose M.D. Director
Age: 63
Bio & Compensation  - Reuters
W. Gerald Gerald Austen M.D. Independent Director
Age: 84
Bio & Compensation  - Reuters